P2RY12 and atrial fibrillation: The results showed that the antithrombotic regimen with apixaban had caused no significant differences in ischemic events but resulted in less bleeding and fewer hospitalizations when compared to a regimen including VKA, aspirin, or both.24 ENTRUST AF PCI (randomized, multicenter, open‐label trial) was performed to determine the safety of edoxaban plus P2Y12 inhibitor in patients with AF who had PCI and results showed that edoxaban‐based regimen was noninferior to VKA regimen for bleeding, without having significant differences in ischemic events.25